Emma L. Murray

Emma L. Murray is a patent litigation attorney whose practice at Goodwin Procter primarily focuses on biosimilars and pharmaceutical matters, though she has also been involved in software patent litigation. She is an Associate in the firm's Litigation department, having joined in 2023, and contributes to Goodwin's "Big Molecule Watch" blog, which provides analysis on regulatory issues, litigation, and legislation in the biosimilars field. Her contributions highlight her engagement with complex issues in pharmaceutical patent enforcement and regulatory approvals, including cases involving mRNA patents and biosimilar approvals.

In terms of litigation experience, Ms. Murray appeared as Of Counsel for the plaintiff, X1 Discovery, Inc., in the case X1 Discovery, Inc. v. Microsoft Corporation. This case involved allegations of patent infringement related to search or discovery software. While her tracked appearance is on the plaintiff side, her broader contributions suggest a practice that addresses the interests of innovator pharmaceutical companies in defending their intellectual property.

Ms. Murray's academic background includes a J.D. from Washington University School of Law, awarded in 2023, and a B.S. in Pharmacology & Toxicology from the University of Wisconsin-Madison, obtained in 2019. She is admitted to practice in Massachusetts and before the U.S. Patent and Trademark Office (USPTO). While her firm's biosimilars blog tracks PTAB activity, specific details regarding her individual PTAB or IPR experience are not extensively detailed in public profiles.